rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

aTyr Pharma, Inc.

ATYR · Nasdaq

Health CareBiotechnologyNot moving yet

ATYR stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 68.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$100K
Insider sales, 12 months
$13K
Officials’ trades on record
0
Institutions holding
86 (-19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$879KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months3
Buyers · sellers1 · 3
WhoDidSharesTraded
Paul SchimmelDirectorbought100,000at $0.496327 May 2026filed 28 May 2026
Nancy DenyesGeneral Counselsold1,118at $0.97614 Feb 2026filed 4 Feb 2026
Jill Marie BroadfootChief Financial Officersold1,558at $0.9764 Feb 2026filed 4 Feb 2026
Sanjay ShuklaPresident and CEOsold3,745at $0.9764 Feb 2026filed 4 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders86-19 on the quarter
New · exited17 · 36
Reported value$21.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FEDERATED HERMES, INC.reduced · filed 12 Aug 20268,509,678$5.1M-2,000,000−19.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20263,808,091$2.3M-4,041−0.1%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20262,610,548$1.6M+2,114,530+426.3%
FMR LLCreduced · filed 13 Aug 20262,471,418$1.5M-12,235,425−83.2%
BlackRock, Inc.reduced · filed 7 Aug 20261,827,332$1.1M-4,616,572−71.6%
Kalehua Capital Management LLCnew · filed 14 Aug 20261,788,167$1.1M+1,788,167
JANE STREET GROUP, LLCadded · filed 14 Aug 20261,721,297$1.0M+1,672,795+3448.9%
UBS Group AGreduced · filed 13 Aug 20261,531,151$914K-2,336,062−60.4%
MORGAN STANLEYadded · filed 13 Aug 20261,343,636$802K+118,169+9.6%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,245,147$743K+100,582+8.8%
31 Mar 2023 – 30 Jun 2026
3870102Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Brandon Yaras Company insiderChief Financial Officer · last 1 Oct 20260 · 0
Paul Schimmel Company insiderDirector · last 27 May 202630 · 1
Eric Benevich Company insiderDirector · last 11 May 20260 · 0
Jane A. Gross Company insiderDirector · last 11 May 20261 · 0
Sara Zaknoen Company insiderDirector · last 11 May 20260 · 0
Svetlana Lucas Company insiderDirector · last 11 May 20260 · 0
Timothy Coughlin Company insiderDirector · last 11 May 20261 · 0
Jill Marie Broadfoot Company insiderChief Financial Officer · last 4 Feb 20266 · 6
Nancy Denyes Company insiderGeneral Counsel · last 4 Feb 20261 · 4
Sanjay Shukla Company insiderPresident and CEO · last 4 Feb 202612 · 3
John K. Clarke Company insiderDirector · last 22 May 20240 · 5
Jeffrey S. Hatfield Company insiderDirector · last 6 May 20200 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-99.7%
Share count trendFY 2025 · to 2 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$10.7M
Free cash flowFY 2025 · to 31 Dec 2025−$62.1M

Analyst forecasts

No analyst forecasts yet.